AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05534022 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Test myopia control lenses (BSL)
Description: Myopia control spectacle lenses (test lenses) will be given to subjects throughout the 24 months trial.
Study NCT06412653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Acetate Dihydrate
Description: In this single arm trial, all participants will be receive the trial drug zinc acetate dihydrate orally. The Investigational medicinal product (IMP) will be given one hour after meal in a dosage which is recommended in Wilson Disease and has been given in this condition without observing severe adverse effects. If oral administration is not possible due to the disability level of the patient, the IMP can be mortared and suspended and can then be given as suspension orally or via the Percutaneous endoscopic gastrostomy. The total treatment duration in each patient is 6 months with stable dosage over the duration of the trial. If the therapy shows effects, the parents and participants may continue medication after the end of the trial. If not, they will stop the medication after the last visit at the trial site.
Study NCT05298150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dynamic cycling
Description: The dynamic cycling involves smart bike that changes according to participants' performance.
Study NCT05298150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forced cycling
Description: The same smart bike as used for dynamic cycling, but its adaptive capacity will be disabled. In this case, the bike will behave as standard exercise stationary bike. It will not change its performance according to participants' response.
Study NCT05997264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909 Full Dose (0.5 mL)
Description: AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for PEP of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
Study NCT05997264 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909 Half Dose (0.25 mL)
Description: AV7909 Anthrax Vaccine is being developed by Emergent Product Development Gaithersburg Inc. (Emergent) for PEP of disease in persons 18 through 65 years of age following suspected or confirmed B. anthracis exposure when administered in conjunction with the recommended antibacterial regimen. AV7909 is a combination product containing BioThrax and CPG 7909, a synthetic immunostimulatory oligodeoxynucleotide that has been shown to be a potent vaccine adjuvant. CPG 7909 is a Toll-like receptor 9 agonist designed to induce both an enhanced antigen-specific antibody response and a natural killer T-cell immune response when used in combination with prophylactic (preventative) or therapeutic vaccines.
Study NCT06577623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINDful TIME
Description: Group-based psychoeducational mindfulness-based intervention.
Study NCT05864781 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Jigsaw Technique
Description: Jigsaw technique is one of the cooperative learning methods. A topic planned to be learned in the lesson is divided into sections and these sections are distributed to the students in the main group. Students who are responsible for the same sections in the groups combine to form expert groups and specialize by working on the subject. They then return to their main group to share their knowledge and make a presentation on the topic.
Study NCT06329492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)
Description: Your blood will be processed into Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP in the procedure room with you while you wait. This will take approximately 30 minutes. When this is complete, an ultrasound will be done of your knee to determine the best location for injection into the knee joint. You will undergo an ultrasound guided injection, and the needle guided into the knee joint, and the Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) A2MRP will be injected into the joint space. If there is excessive fluid in your knee, this may be drained before the injection is performed. The needle will be removed, and a band aid will be placed over the injection site.
Study NCT06100419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: serratus posterior superior intercostal plane block
Description: With this newly introduced procedure added to the literature, patients undergoing breast surgeries are expected to experience reduced pain.
Study NCT06239870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab combined with chemoradiotherapy in the whole course of neoadjuvant therapy
Description: Each enrolled patient was given 2 cycles of induction chemotherapy combined with immunization, followed by immunization combined with chemoradiotherapy, and finally 2 cycles of consolidation chemotherapy combined immunization
Study NCT06491472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab
Description: 20mg/kg,IV,d1,Q3W
Study NCT06491472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2, IV, d1/8, Q3W
Study NCT06491472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: 125mg/m2, IV, d1/8, Q3W
Study NCT06491472 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 5Gy \*5 F
Study NCT05795101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
Study NCT05795101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: via IV, protocol determined dosage once per cycle up to eight cycles. Each cycle will last for 21 days (three weeks).
Study NCT05872568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Description: The recommended dose range is 360 to 720mg,bid
Study NCT05872568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Description: The recommended dose range is 360 to 720mg,bid
Study NCT05753150 — intervention group
Intervention type: DRUG
Intervention: Tafenoquine
Description: Tafenoquine 300 mg (2x150 mg tablets)
Study NCT05753150 — intervention group
Intervention type: DRUG
Intervention: Primaquine
Description: Daily primaquine adjusted by weight (0.25 mg/kg/day for 14 days)
Study NCT05753150 — intervention group
Intervention type: DRUG
Intervention: Primaquine
Description: Weekly primaquine adjusted by weight (0.75mg/kg/week for 8 weeks)
Study NCT05011994 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance intervention
Description: The intervention consists of action planning, text messages, and coordinator support.~At onset, each participant creates an action plan for physical activity with the help of a health professional:~* What types of physical activities?~* When and how often?~* Where and with who?~  2 auto-generated text messages are sent weekly for a duration of 12 weeks. The first prompts physical activity. The second asks if plans were reached. If yes, an automatic reply with positive reinforcement is generated. If no, an automatic reply asks if the participant wants to be contacted.~Participants are contacted by a coordinator either by answering text messages or if not answering the texts for a period of 2 weeks or more. Coordinator functions:~* Call participants replying to texts that they wish to be contacted~* Help participants establish contact to local activities involving physical activity~* Follow-up on and adjustment of action plan~* Offer guidance in physical activity
Study NCT05435781 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
Study NCT05435781 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for hydrocortisone
Description: Patients are randomised to either placebo or hydrocortisone supplemental doses in situations of stress. Patients will continue prednisolone treatment and tapering hereof according to current clinical guidelines for PMR/GCA , prednisolone is not part of the intervention.
Study NCT05080777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Savvy
Description: A low-risk, psychoeducational, group-based intervention, is grounded in social learning and stress process theory and its main goal is to produce improved caregiver mastery over the symptom management skills commonly encountered when supervising and caring at home for an older adult living with ADRD. Over the 7-week program, there are synchronous and asynchronous activities each week. The synchronous portion includes weekly scheduled videoconferences (60-80 min) that serve as an online classroom in which facilitators lead lectures and discussions. Daily, caregivers access online 6- to 15-min prerecorded videos, each focused on one main learning objective. Caregivers can watch the lessons whenever and as often as they wish.
Study NCT05080777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caregiving During Crisis (Educational Program)
Description: The attention control group will receive the self-guided Caregiving During Crisis program. Caregiving During Crisis is a fully online, asynchronous, professionally designed continuing education course aimed at developing the competency of informal caregivers of community-dwelling persons living with dementia to ensure the safety of that person and themselves during this time of the COVID-19 pandemic. The course, readily accessible by home computer or smartphone, describes methods of home infection control and prevention to create a Safe Home space, strategies for safely leaving and re-entering the home (e.g., to shop), additional strategies for safely allowing service personnel (e.g., home health aides or electricians) and select family members to enter the Safe Home space, and risk management strategies to frame decisions when/if COVID restrictions are relaxed or revoked.
Study NCT06221579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No intervention, interviews with MCI patients as part of the development phase
Description: No intervention, interviews with MCI patients as part of the development phase
Study NCT06334523 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ventilation
Description: the premature infant will be ventillad by respirator and medical device S-lem for reduce the Continuous Tracheal Gas Insufflation (CTGI). The CTGI is a ventilation option conventional to reduce or even cancel space anatomical death due to respiratory prostheseses.
Study NCT05089838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV-TCR-T cells
Description: Patients who developed refractory CMV infection after allo-HSCT will be enrolled, and donor derived CMV-TCR-T(HLA-A\*1101\\0201\\2402) cells will be intravenously infused with a escalated dose of 0.3-1×10E7CMV-TCR-T cells. The CMV DNA copies and CMV-TCR-T cell proliferation will be monitored in the scheduled time (day 0, day 4, day 7, day 10, day 14,day 28).
Study NCT06294496 — intervention group
Intervention type: PROCEDURE
Intervention: CEA/CAS
Description: carotid endarterectomy (CEA) and carotid artery stenting (CAS)
Study NCT04848428 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online mindfulness-based cognitive therapy
Description: The first session will first focus on providing feedback regarding post-surgical pain. The second session will focus on teaching mindfulness strategies. The third session will focus on practicing one of the two strategies. Of note, sessions 2 and 3 will start with cognitive restructuring strategies for the moderate-high risk profile patients. The 4th session consists in a booster providing feedback and reminders about cognitive reactions to pain and mindfulness meditation. The participants will be asked to practice meditation 5 days a week, for a total of 4 weeks
Study NCT04848428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online standardized education
Description: One 15-minute educational session on postoperative pain, the relationship between pain, thoughts and emotions and brief overview of strategies.
Study NCT04621110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal dexmedetomidine
Description: Dexmedetomidine (precedex®) will be administered by intranasal route in 1ug/kg each dose, repeating at most 3 times to see if it can give enough sedation to painful procedure. To assess the level of sedation the study will use Ramsay sedation scale.
Study NCT04621110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal fentanyl
Description: Fentanyl will be administered by intranasal route in 1,5ug/kg each dose, repeating at most 3 times to see if it can give enough pain relief for painful procedure. To assess pain control the study will use Face, Legs, Activity, Cry, Consolability scale ( FLACC)
Study NCT04621110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous ketamine (ketalar®)
Description: Ketamine (ketalar®) will be administrated by intravenous route in 1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
Study NCT04621110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous midazolam
Description: Midazolam will be administrated by intravenous route in 0,1mg/kg dose and the study will use this drug to compare the efficiency of intranasal drugs.
Study NCT04839965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ampion
Description: Ampion administered via intravenous infusion
Study NCT04839965 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo administered via intravenous infusion
Study NCT06084455 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 30 minutes of aerobic exercise on a stationary bike
Study NCT04896268 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency
Description: Rafaelo's technique consists of delivering a low-temperature 4 MHz radiofrequency wave current into the haemorrhoidal vascular tissue using a large single-use needle with microfibre electrodes at the end.
Study NCT04896268 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arterial ligation then recto-anal repair with Doppler
Description: The aim of arterial ligation is to de-arterialise the haemorrhoids by reducing the arterial flow of the haemorrhoidal plexuses while avoiding obstructing the venous return.
Study NCT05068414 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood panel
Description: * Thrombin generation test~* Residual plasma concentration of dabigatran, rivaroxaban and/or apixaban (direct oral anticoagulants)~* International Normalized Ratio (if anti-vitamin K therapy is prescribed)~* Platelet aggregation test
Study NCT06461130 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group
Description: Group of people doing dual tasks during double-leg cycling training.
Study NCT06461130 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The group that received only aerobic exercise.
Study NCT05290831 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VitalPatch
Description: The VitalPatch continuously monitors skin temperature, activity, and electrocardiography.
Study NCT05166044 — intervention group
Intervention type: BIOLOGICAL
Intervention: EV71 Inactivated Vaccine
Description: The EV71 vaccine was manufactured by Sinovac Biotech Co,And inactivated EV71 virus antigen was no less than 3.0EU in 0.5 mL of aluminium hydroxide solution per injection.
Study NCT04852016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consent process with the addition of Digital educational platform (DEP)
Description: In-patients being consented for laparoscopic cholecystectomy will be provided with a Digital Educational Platform (DEP), in the form of modules on an iPad. These participants will still undergo the usual standard verbal consent (SVC). Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using DEP.
Study NCT04852016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Consent process using the standard verbal consent (SVC)
Description: In-patients being consented for laparoscopic cholecystectomy will go through the SVC. Multiple choice questionnaires will be given pre and post consent to determine acquisition and retention of the information provided using SVC.
Study NCT04717726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk Thistle (MT)
Description: Participants in the MT and EX + MT groups will be provided 900 mg of standardized milk thistle extract daily (300 mg three times per day before meals) over the 12-week regimen. We will use the standardized Jarrow Formulas Milk Thistle Veggie Caps containing 30:1 extract that is standardized to contain 80% total Milk Thistle seed flavonoids (polyphenols), including the critical Silymarin fractions isosilybinins A and B, silybinins A and B, silychristin and silydianin that is active against suppressing the UGT1A1 enzyme increasing plasma bilirubin. The capsules are free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Rationale for using this brand: There have been inconsistencies with previous studies that did not use a standardized silymarin extract, which may have contained low levels of the active polyphenolic flavonoids in the milk thistle plant, which varies in the plant's stems, leaves, roots, and flowers.
Study NCT04717726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Gasseri (LAC)
Description: Participants in the LAC and LAC + EX groups will receive two doses of 3 billion CFU of lactobacillus gasseri per day for a total of 6 billion CFU, the recommended upper level for supplementation of probiotic cultures. We will use Swanson brand Lactobacillus gasseri, whose capsules are also free of wheat, gluten, soybeans, dairy, egg, fish/shellfish, peanuts/tree nuts, and GMOs. Importantly, this brand uses acid-resistant designed release capsules to improve the viability of the lactobacillus in the human stomach.
Study NCT04717726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Description: Participants in the EX, EX + MT, and EX + LAC groups will complete five weekly exercise sessions on their own, expending roughly 600 kcal per session. Participants will be provided a Polar A-300 heart rate monitor programmed for their individual attributes (height, weight, age, training status, gender), which gives a real-time estimate of energy expenditure during exercise. Participants will report to the lab once per week to download the exercise sessions and verify compliance. If participants are not compliant (defined as completing 85% of their assigned exercise sessions per month), they will be disqualified. This intervention has been successfully used by Dr. Flack in multiple studies to produce significant weight loss without dietary intervention in this population with a retention rate of over 90%
Study NCT06326398 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stoma Care
Description: Nursing students practice stoma care with low and high fidelity simulation
Study NCT04717726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control (CON)
Description: Participants in the CON and EX group will receive a placebo (maltodextrin) made to look identical to the MT and LAC capsules.
Study NCT04717726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control (CON)
Description: Participants in the CON and EX group will receive a placebo (maltodextrin) made to look identical to the MT and LAC capsules.
Study NCT04578327 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prosthetic hand
Description: Different types of conventional prosthetic limbs will be used by subjects.
Study NCT04578327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Interface
Description: Different types of peripheral nerve stimulation will take place
Study NCT05496374 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo-matching capsules will be administered orally.
Study NCT05496374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720 500 mg
Description: SPR720 500 mg (250 mg × 2 capsules) will be administered orally.
Study NCT05496374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPR720 1000 mg
Description: SPR720 500 mg (250 mg × 4 capsules) will be administered orally.
Study NCT04960865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Taping under tension.
Description: Kinesio tape will be applied to participants under tension.
Study NCT04960865 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesio Tape without tension
Description: Kinesio tape will be applied to participants without any tension.
Study NCT04960865 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Rigid Taping
Description: Rigid Taping will be applied.
Study NCT01204827 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 13C Methacetin Breath Test (BreathID)
Study NCT05541016 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood and saliva specimen collection for NavDx testing